Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.74 |
| ▸ | PKM | P14618 | 6/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | GLA | P06280 | 3/20 | 0.71 |
| ▸ | GAA | P10253 | 3/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14133805 | 0.93 | KDM4E (0.71) | KDM4EALDH1A1PKMMAPTGLA | |
| SCHEMBL14133539 | 0.91 | ALDH1A1 (0.75) | KDM4EALDH1A1PKMMAPTGLA | |
| SCHEMBL14133770 | 0.88 | KDM4E (0.83) | KDM4EALDH1A1PKMMAPTGLA | |
| SCHEMBL14133935 | 0.88 | KDM4E (0.83) | KDM4EALDH1A1PKMMAPTGLA | |
| SCHEMBL14133533 | 0.85 | KDM4E (0.71) | KDM4EALDH1A1PKMMAPTGLA | |
| SCHEMBL14133536 | 0.85 | PKM (1.00) | KDM4EALDH1A1PKMMAPTGLA | |
| SCHEMBL14133277 | 0.83 | KDM4E (1.00) | KDM4EALDH1A1PKMMAPTGLA | |
| SCHEMBL14133452 | 0.83 | KDM4E (0.68) | KDM4EALDH1A1PKMMAPTGLA | |
| SCHEMBL14133394 | 0.83 | KDM4E (0.68) | KDM4EALDH1A1PKMMAPTGLA | |
| SCHEMBL14133395 | 0.82 | ALDH1A1 (0.74) | KDM4EALDH1A1PKMMAPTGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012160447-A1 | 3, 5 -DIPHENYL- SUBSTITUTED PYRAZOLINES FOR THE TREATMENT OF CANCER, PROLIFERATIVE, INFLAMMATORY OR AUTOIMMUNE DISEASES | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2012-11-29 | — | — | WO | disclosed |
| US-20120302609-A1 | Pyrazolines for the Modulation of PKM2 | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2012-11-29 | — | — | US | disclosed |
| US-20120302609-A1 | Pyrazolines for the Modulation of PKM2 | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302609-A1 | Pyrazolines for the Modulation of PKM2 | PDK2, PDK4, PDK3 | KDM4E 376/4885ALDH1A1 2476/4885PKM 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.